Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancers these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women. The symptoms of kidney cancer/ renal cell carcinoma (RCC) include a lump or mass in the abdomen or side, blood in the urine, weight loss, fever, and lethargy. Several drugs for the treatment are currently available in the market.

Market Overview:

The latest research study on the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market finds that the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market reached a value of USD 6825.96 million in 2022. It’s expected that the market will achieve USD 8641.21 million by 2028, exhibiting a CAGR of 4.01% during the forecast period.

Risk Assessment on COVID-19

COVID-19 is not only a global pandemic and public health crisis; it has also severely affected the global economy and financial markets. Significant reductions in income, a rise in unemployment, and disruptions in the transportation, service, and manufacturing industries are among the consequences of the disease mitigation measures that have been implemented in many countries. A year and a half since the onset of the COVID-19 pandemic, the global economy is poised to stage its most robust post-recession recovery in 80 years in 2021. But the rebound is expected to be uneven across countries, as major economies look set to register strong growth even as many developing economies lag.

Global growth is expected to accelerate to 5.6% this year, largely on the strength in major economies such as the United States and China. And while growth for almost every region of the world has been revised upward for 2021, many continue to grapple with COVID-19 and what is likely to be its long shadow. Despite this year’s pickup, the level of global GDP in 2021 is expected to be 3.2% below pre-pandemic projections, and per capita GDP among many emerging market and developing economies is anticipated to remain below pre-COVID-19 peaks for an extended period. As the pandemic continues to flare, it will shape the path of global economic activity. Many countries impose lockdowns to curb the spread of the pandemic. This has negatively affected the availability of labor, resulting in less or no production.

Market Development Constraints

The high cost associated with kidney cancer and renal cell carcinoma (RCC) drugs is a major problem faced by citizens of many countries. The pressure to control costs and demonstrate value is widespread. Political uncertainty and continued economic pressure in many countries have caused people to question the sustainability of public healthcare funding. In less affluent countries, the lack of cost-effective drugs affects the health of the population and leads to lower average life expectancy. Therefore, pharmaceutical companies are facing pressure to reduce drug prices. The high costs associated with drugs are putting pressure on the revenues of kidney cancer and renal cell carcinoma (RCC) drug manufacturers.
Fierce competition in the kidney cancer and renal cell carcinoma (RCC) drugs market is inevitable. Established companies that have not yet entered the preparatory field have more ideas to wait and consider or consider entering the preparatory field. Some intermediate and raw material manufacturers have planned to expand their production capacity. The kidney cancer and renal cell carcinoma (RCC) drugs price war continues. Therefore, this variety, especially in intermediate products, will undergo a process of competition and gradual integration.

Region Overview:

From 2023-2028, North America is estimated to witness robust growth prospects.

Company Overview:

Pfizer, Inc., Novartis Ag, Roche Holding AG, BMS and Exelixis are the five key players in the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market. These companies have shown consistent growth in revenue, larger volumes of sales and a prominent presence in terms of share in the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market in the past 5 years.

Pfizer, Inc.

The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines.

Novartis Ag is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Segmentation Overview:

Among different product types, Angiogenesis Inhibitors segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Renal cell carcinoma (RCC) segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market covered in Chapter 3:

Roche Holding AG
BMS
Pfizer, Inc.
Clinigen
Exelixis
Novartis Ag
Bayer AG
Amgen

In Chapter 4 and Chapter 14.2, on the basis of types, the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market from 2018 to 2029 is primarily split into:

Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market from 2018 to 2029 covers:

Renal cell carcinoma (RCC)
Transitional cell carcinoma (TCC)
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)